The development of clinically relevant pharmacological inhibitors to block the function of both PI3K/AKT/mTOR and MAPK/MEK/ERK could provide new avenues for well-designed studies that assess the tolerability and efficacy of a new therapeutic approach for the treatment of melanoma. Here, AKT1 is linked to melanoma.